OR WAIT null SECS
January 25, 2022
UCB and Zogenix have agreed to an acquisition deal totaling nearly $2 billion.
Merck and Ridgeback Therapeutics will supply UNICEF with up to three million capsules of molnupiravir through the first half of 2022.
January 21, 2022
PharmaLex Group has merged with MAP Group, broadening its market access expertise and extending its reach into the Italian marketplace.
Colorcon Ventures is investing in a provider of intelligent manufacturing execution systems (MES), Apprentice.io.
January 18, 2022
In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.
After a previously announced merger, Protagen Protein Services, BioAnalytix, and GeneWerk have formed a new CRO under the name ProtaGene.
January 17, 2022
Pfizer will pay Beam $300 million upfront to conduct research on three undisclosed base editing targets in the liver, muscle, and central nervous system.
January 14, 2022
Fosun Pharma and Insilico Medicine will collaborate on AI-driven drug discovery and development of product candidates targeting multiple disease targets.
January 13, 2022
The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.
January 11, 2022
The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.